Neurotech Pharmaceuticals, Inc. Receives Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a Treatment for Macular Telangiectasia Type 2 (MacTel).

Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma.

InnoCare Announces the Acceptance of Biologics License Application for Tafasitamab in Combination with Lenalidomide for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Adult Patients in China.

Silence Therapeutics Announces Positive Topline 48-Week Data from Phase 2 Study of Zerlasiran in Patients with Elevated Lipoprotein(a).

Sarepta Therapeutics Announces Expanded US FDA Approval of ELEVIDYS to Duchenne Muscular Dystrophy Patients Ages 4 and Above.

FDA Greenlights Merck’s KEYTRUDA® (pembrolizumab) Combined with Carboplatin and Paclitaxel for Treating Adults with Advanced or Recurrent Endometrial Cancer.

Marea Therapeutics, a biotechnology enterprise focused on clinical-stage developments and backed by Third Rock Ventures, is dedicated to creating innovative treatments for cardiometabolic disorders.

Day One Enhances Pipeline with Innovative Clinical-Stage ADC Targeting PTK7 for Solid Tumors in Adults and Children.

This trial assesses SCB-1019, Clover’s bivalent RSV prefusion-stabilized F (PreF)-Trimer subunit vaccine candidate, developed using the company’s proprietary Trimer-Tag vaccine technology platform.

Spyre Therapeutics Begins Phase 1 Trial with Initial Doses of SPY001, a New Long-acting anti-α4β7 Antibody, for Inflammatory Bowel Disease Treatment.

FDA has approved SKYRIZI® (risankizumab-rzaa) for treating ulcerative colitis, broadening AbbVie’s inflammatory bowel disease treatment options.

Sobi revealed that the European Commission has approved the Marketing Authorisation for ALTUVOCT™ (efanesoctocog alfa) for the treatment and prevention of bleeding episodes and perioperative prophylaxis in patients with haemophilia A.